Roche licenses neurodegenerative programmes

Roche has licensed two preclinical programmes focused on therapeutics to slow down neurodegenerative disorders from reMYND, a small Belgian biotechnology company. The deal that could be worth more than €500 million to reMYND in milestone and other payments, including an undisclosed upfront payment, plus royalties on any resulting product sales.

Roche has licensed two preclinical programmes focused on therapeutics to slow down neurodegenerative disorders from reMYND, a small Belgian biotechnology company. The deal that could be worth more than €500 million to reMYND in milestone and other payments, including an undisclosed upfront payment, plus royalties on any resulting product sales.

The reMYND programmes target the inhibition of alpha-synuclein neurotoxicity in Parkinson's disease and tau neurotoxicity in Alzheimer's disease. As a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Alimentary/Metabolic

Protagonist Hopes To Come From Behind In Obesity With Oral Triple Agonist

 

The company announced plans to move an oral GLP-1/GIP/GCG receptor agonist peptide into clinical development for obesity in 2026.

Altimmune’s Phase IIb MASH Data Send Share Price Plunging

 
• By 

Altimmune’s stock price did not recover on June 27, after a 57% dip the day before, despite efforts to position pemvidutide as both resolving MASH and offering weight loss.

Veru’s Enobosarm Market Potential Enhanced By New Obesity Data

 
• By 

The late-stage biotech posted results from the maintenance extension portion of its Phase IIb QUALITY trial in which enobosarm reduced weight regain and helped preserve lean mass in patients who discontinued their semaglutide weight-loss treatment.

Battle For Obesity Market Shifts Gears in India: Will Wegovy Trump Mounjaro?

 

Novo Nordisk debuts Wegovy in India, gears for pole position in obesity. The Danish group’s leadership doesn’t appear too perturbed about the head start for Lilly’s Mounjaro or the imminent arrival of generic semaglutide next year.

More from Therapeutic Category

Protagonist Hopes To Come From Behind In Obesity With Oral Triple Agonist

 

The company announced plans to move an oral GLP-1/GIP/GCG receptor agonist peptide into clinical development for obesity in 2026.

In Brief: Sanofi Cements Support For Adagene

 
• By 

Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.

In Vivo CAR-T Interest Grows With AbbVie Acquisition

 

Acquiring Capstan gives AbbVie a stake in two competing in vivo CAR-T delivery platforms, with the field's first readouts expected in 2026.